EGFR and neoplasm: Opportunity exists to explore methods to enhance lesional absorbed dose such as the concomitant use of drug therapy which may radiosensitize tumours (e.g. chemotherapy +/− anti-EGFR monoclonal antibodies or bevacizumab).